- Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed psychiatrist Fred Grossman, D.O., FAPA, to its Board of Directors. Dr. Grossman has over two decades of experience in clinical development and medical affairs, ph

Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a business update and re

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion's fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023. The Company will hold a conference call and webcast to discuss its results at 8:30 a.m. ET the same day. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conferen

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published The American Psychedelic Practitioners Association (APPA) and BrainFutures have published the first-ever set of professional practice guidelines for the provision of psychedelic-assisted therapy. APPA is the national entity advocating for the integration of psychedelics into the U.S. healthcare system.  The partners say the specificity of the psychedelic therapy model -combining psychedelic administration and therapy in the same session- calls for practitioners to hold “new processes and competencies.” Learn more HERE. DMT As A Treatment For Stroke? Phase 2 Study Looks Closer Algernon NeuroScience (AGN

Clinical-stage psychedelics biotech Reunion Neuroscience (NASDAQ:REUN) and MPM BioImpact have completed their announced plan of arrangement for MPM’s acquisition of Reunion for approximately $13.1 million.  The company’s shareholders approved the transaction proposal at a special meeting on July 12, and the Ontario Superior Court of Justice for commercial list did so on July 14. Following Section 192 of the Canadian BCA and terms and conditions of the definitive arrangement agreement dated May 31, all holders of Reunion’s outstanding common shares are entitled to receive $1.12 in cash for each share held immediately prior to the effective time of the arrangement. All registered shareholde

Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal prosecution for possession, use, purchase, cultivation and engaging in practices with “entheogenic plants or plant compounds." The order also averts the use of local resources in support of federal and state actions against the substances “unless required by law.” The edict only applies to “natural” substances and excludes any synthetic ones. Moreover, it doesn’t refer to them as “psychedelics,” but instead as “naturally-occurring psychoactive compounds” or “entheogens.” Keep reading HERE. Germ

As Reunion Neuroscience (NASDAQ:REUN) and Mindset Pharma (OTC:MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph, reported Noah Smith. 4-HO-DiPT is a psychedelic compound with LSD and psilocin-like effects, but holding a shorter onset of action and duration. Reunion filed a lawsuit against Mindset Pharma back in March, stating the latter’s purposeful copy of its lead drug candidate RE104 and its following IP claims, which eventually obstructed Reunion’s operations forward. Terran Biosciences has filed a patent application for solid forms of 4-OH-DiPT hemi

Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ:REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12. Following suit, the Ontario Superior Court of Justice granted a final order approving the proposed arrangement under Section 192 of Canada’s BCA. Both companies entered a definitive arrangement agreement for the acquisition of Reunion in an all-cash transaction of $13.1 million this past May 31. They anticipate closing on or about July 21, 2023. The arrangement resolution required the approval of at least two-thirds (66%) of the votes cast by

https://www.marijuanamoment.net/california-psilocybin-legalization-campaign-cleared-to-collect-signatures-for-2024-ballot-initiative/ California officials have cleared a campaign to begin signature gathering for a 2024 ballot initiative to legalize the possession, sale and regulated therapeutic use of psilocybin. It’s one of at least two campaigns in the state that are seeking to enact psychedelics reform through the ballot process next year. Decriminalize California, which has previously sought ballot placement for similar measures in two prior election cycles, announced over the weekend that the state attorney general’s office approved the title and summary for the current initiative on

https://www.marijuanamoment.net/bipartisan-lawmakers-push-for-marijuana-and-psychedelics-amendments-to-defense-bill-but-committee-action-is-delayed/Bipartisan lawmakers pushed for the adoption of marijuana and psychedelics amendments as part of a large-scale defense bill at a House committee meeting on Tuesday—but the proposals' fate remains uncertain following complications over unrelated measures being pushed by conservative members.The House Rules Committee did clear 290 largely non-controversial amendments to the National Defense Authorization Act (NDAA) for floor votes as the leadership negotiates with House Freedom Caucus members who are demanding adoption of contentious measures on is

World's Largest Psychedelics Conference Boasts 12K Attendees The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gathered over 12,000 people from the entire psychedelics spectrum. The list of attendees included the most knowledgeable individuals in the field, as well as grassroots organizations, practitioners, scientists, politicians, veterans, celebrities, publicly traded companies and psychonauts including famed podcast host Dr. Andrew Huberman; NFL star quarterback Aaron Rodgers; and actor Jaden Smith, who advocate awareness expansion and access to psychedelic-assisted therapies as mental health treatment

Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ:REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the report: Cash and cash equivalents of $20.9 (CA$27.7) million as of March 31, compared to $48 million held on the same date in 2022. R&D expenses of $3.3 and $9.8 million for the three and twelve-month periods, compared to $1.7 and $5.3 million for the same periods in 2022.  G&A expenses of $3 and $9.8 million for the three and twelve-month periods ended March 31, 2023 compared to $2.3 and $8.3 million for the same periods in 2022.  Cash used in operating activities totaled $21 mil

Reunion Neuroscience (NASDAQ:REUN) reported its Q4 earnings results on Thursday, June 29, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Reunion Neuroscience missed estimated earnings by 41.38%, reporting an EPS of $-0.41 versus an estimate of $-0.29. Revenue was down $1.36 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.16 which was followed by a 0.8% increase in the share price the next day. To track all earnings releases for Reunion Neuroscience visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.